NCT00101569已完成3 期
Aripiprazole Oral Acceptability Trial
Otsuka Pharmaceutical Development & Commercialization, Inc.1 个研究点 分布在 1 个国家目标入组 59 人开始时间: 2004年3月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 59
- 试验地点
- 1
- 主要终点
- acceptability
研究概览
简要总结
The purpose of this trial is to study liquid aripiprazole in patients with stable schizophrenia.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Stable patients currently receiving aripiprazole or other antipsychotic medications.
排除标准
- 未提供
研究组 & 干预措施
A1
Experimental
干预措施: Aripiprazole (Drug)
A2
Experimental
干预措施: Aripiprazole (Drug)
结局指标
主要结局
acceptability
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Safety and Tolerability Trial of Aripiprazole IM Depot Treatment in Adult Subjects With Schizophrenia Stabilized on Oral Antipsychotics Other Than AripiprazoleSchizophreniaNCT01552772Otsuka Pharmaceutical Development & Commercialization, Inc.60
已完成
4 期
Aripiprazole for the Treatment of Schizophrenia With Co-Morbid Social AnxietySchizophreniaSchizoaffective DisorderSocial Anxiety DisorderNCT00177008University of Medicine and Dentistry of New Jersey18
已完成
3 期
Aripiprazole in Adolescents With SchizophreniaSchizophreniaNCT00102063Otsuka Pharmaceutical Development & Commercialization, Inc.302
已完成
3 期
Aripiprazole for Schizophrenia Outpatients Completing BMS Clinical TrialsSchizophreniaNCT00239356Otsuka Pharmaceutical Development & Commercialization, Inc.119
终止
4 期
Best Event Schizophrenia Trial--A Randomized Double-Blind Trial of Aripiprazole and Risperidone in SchizophreniaSchizophreniaNCT00712270Kettering Health Network21